Estramustine (EM) has clinical utility in the treatment of prostate malignancies, although its pharmacological activity is independent of its constituent steroid/alkylating agent moieties. The objective of this proposal is to delineate the mechanism(s) by which EM induces cytotoxicity in normal, benign and malignant human prostate cells. By combining EM with dansyl chloride, a novel fluorescent probe (DNS-EM) is available to study drug uptake and intracellular distribution. Following chemical characterization and provide the biological activity of EM is not compromised by the dansylation, this compound may prove to have long term potential application in studies of EM's effects in animals and man. Using whole mount and thin section electron microscopy to investigate the effects of EM on microtubules, the cytomatrix and aspects of mitotic spindle organization, studies will focus on whether EM induces aberrations in the binding of microtubule associated proteins (MAP's) to microtubule components and to other cytoplasmic elements. The availability of specific monoclonal antibodies raised against MAP antigens will permit immunofluorescent microscopy studies of drug effects in short-term human prostate cultures and in an established human prostatic carcinoma cell line. EM may prove to be as useful to the study of MAP distribution and function as colchicine has been to the study of tubulin. In addition, it may represent a new class of antitumor drugs with anti-cytomatrix effects distinct from other chemotherapeutic agents.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA043783-03
Application #
3186123
Study Section
Experimental Therapeutics Subcommittee 2 (ET)
Project Start
1986-03-05
Project End
1989-02-28
Budget Start
1988-03-01
Budget End
1989-02-28
Support Year
3
Fiscal Year
1988
Total Cost
Indirect Cost
Name
Fox Chase Cancer Center
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19111
Ciaccio, P J; Stuart, J E; Tew, K D (1993) Overproduction of a 37.5-kDa cytosolic protein structurally related to prostaglandin F synthase in ethacrynic acid-resistant human colon cells. Mol Pharmacol 43:845-53
Speicher, L A; Barone, L; Tew, K D (1992) Combined antimicrotubule activity of estramustine and taxol in human prostatic carcinoma cell lines. Cancer Res 52:4433-40
Tew, K D; Glusker, J P; Hartley-Asp, B et al. (1992) Preclinical and clinical perspectives on the use of estramustine as an antimitotic drug. Pharmacol Ther 56:323-39
Sheridan, V R; Speicher, L A; Tew, K D (1991) The effects of estramustine on metaphase and anaphase in DU 145 prostatic carcinoma cells. Eur J Cell Biol 54:268-76
Stearns, M E; Wang, M; Tew, K D et al. (1988) Estramustine binds a MAP-1-like protein to inhibit microtubule assembly in vitro and disrupt microtubule organization in DU 145 cells. J Cell Biol 107:2647-56
Stearns, M E; Tew, K D (1988) Estramustine binds MAP-2 to inhibit microtubule assembly in vitro. J Cell Sci 89 ( Pt 3):331-42
Tew, K D; Clapper, M L; Greenberg, R E et al. (1987) Glutathione S-transferases in human prostate. Biochim Biophys Acta 926:8-15